Skip to Main Content

Overview of Projects

The Program of Applied Translational Research (PATR) currently has thirteen projects under way. Below you will find information regarding each of them. If you are interested in learning more about them, you can explore their individual pages or contact us.
Clinical diagnosis of acute interstitial nephritis (AIN) is challenging as there are no reliable non-invasive biomarkers and its diagnosis currently requires a kidney biopsy.
Acute interstitial nephritis (AIN) is a common condition characterized by minimal clinical features and slowly worsening kidney function.
Acute kidney disease (AKD) is a condition characterized by sub-acute loss of kidney function.
In the hopes of discovering therapeutic targets for acute kidney injury, which currently has no specific therapy, the NIH/NIDDK has created the Kidney Precision Medicine Program consortium.
There are over 100,000 patients awaiting a kidney transplant, but only 20% will receive one.
Acute kidney injury (AKI) is a risk factor for chronic kidney disease (CKD) and cardiovascular disease (CVD) with several biological processes orchestrating either recovery or progression to poor long-term outcomes after the initial insult of AKI.
Progression of chronic kidney disease (CKD) in children leads to end stage renal disease (ESRD), which is associated with mortality rates 30-150 times higher than the general pediatric population.
Participation in marathons has gained popularity in the United States with up to 1100 marathons and 507, 600 finishers.
Acute kidney injury (AKI) affects up to 20% of hospitalized patients and increases the risk of dying in the hospital by a factor of 10.
This trial will randomize patients with acute kidney injury (AKI) who are receiving a kidney-toxic medication to alerts (highlighting the particular medication) versus usual care.
This trial will use an advanced machine-learning technique known as uplift modeling to target AKI alerts to a subset of patients who are most likely to be benefited by reducing alert fatigue and improving overall effectiveness.
While AKI carries substantial risk, there remains no therapeutic intervention that can alter the course of AKI once it develops, beyond optimizing usual care.
Our prior research in a mouse model of proteinuric kidney disease revealed upregulation of a protein called histone deacetylase (HDAC).